文献速递脊柱关节炎

银屑病关节炎中抗药抗体的患病率与临床相关性:系统综述

Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.
PubMed 文献 · RMD Open · 2026-08-19

该系统综述纳入28项研究(19项随机对照试验和9项观察性研究),评估银屑病关节炎患者使用bDMARDs时抗药抗体的患病率及其与血清药物水平、临床疗效和安全性的关联。抗药抗体患病率因药物和研究而异,在TNF抑制剂中与较低药物水平和较差临床应答相关,而其他生物制剂类别证据有限。

要点

  • 抗药抗体患病率因bDMARD种类及同一药物不同研究间差异大,免疫测定异质性限制直接比较。
  • TNF抑制剂中抗药抗体与较低血清药物水平和降低的临床应答一致相关,联用甲氨蝶呤与较低抗药抗体患病率相关。
  • IL-17、IL-12/23和IL-23抑制剂的血清药物水平与临床结局数据有限或缺乏,免疫原性相关不良事件不常见。

核心结论

  • 银屑病关节炎中抗药抗体患病率因bDMARD和同一bDMARD的不同研究而异,免疫测定异质性限制可比性。
  • 抗药抗体对TNF抑制剂最具临床相关性,而其他生物制剂类别的证据仍有限。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索MEDLINE、Embase和Cochrane CENTRAL从建库至2025年9月。
  • 纳入报告成人银屑病关节炎患者接受bDMARDs时抗药抗体测量的随机对照试验和观察性研究,共28项研究(19项RCT和9项观察性研究)。
  • 使用Cochrane RoB 2和ROBINS-I评估偏倚风险。

主要发现

  • 抗药抗体患病率在bDMARDs之间及同一药物的不同研究间差异广泛,因免疫测定异质性无法直接比较。
  • 抗药抗体患病率最高见于阿达木单抗、英夫利西单抗和戈利木单抗,其次为乌司奴单抗、依奇珠单抗、培塞利珠单抗和古塞奇尤单抗,而司库奇尤单抗和依那西普免疫原性极低或缺失。
  • 在TNF抑制剂研究中,抗药抗体一致与较低血清药物水平和降低的临床应答相关,联用甲氨蝶呤与较低抗药抗体患病率相关。
  • IL-17、IL-12/23和IL-23抑制剂的血清药物水平和临床结局数据有限或缺乏。
  • 免疫原性相关不良事件不常见,证据不足以确定抗药抗体与bDMARDs不良事件之间的关联。

关键数值与推荐

  • 抗药抗体患病率在bDMARDs之间及同一药物的不同研究间差异广泛,因免疫测定异质性无法直接比较。
  • TNF抑制剂中抗药抗体与较低血清药物水平和降低的临床应答一致相关,联用甲氨蝶呤与较低抗药抗体患病率相关。
  • 司库奇尤单抗和依那西普显示极低或缺失免疫原性。

临床怎么用

  • 对TNF抑制剂治疗应答不佳的银屑病关节炎患者,应考虑抗药抗体导致药物水平降低和疗效下降的可能。
  • 联用甲氨蝶呤可能降低TNF抑制剂的抗药抗体患病率。
  • 其他生物制剂类别中抗药抗体的临床相关性证据有限,需结合具体药物判断。

局限性

  • 免疫测定异质性限制抗药抗体患病率在不同药物和研究间的可比性。
  • IL-17、IL-12/23和IL-23抑制剂的血清药物水平和临床结局数据有限或缺乏。
  • 证据不足以确定抗药抗体与bDMARDs免疫原性相关不良事件之间的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the prevalence of anti-drug antibodies (ADAs) in patients with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) and to evaluate associations with serum drug levels, clinical efficacy and safety. METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic review was conducted. MEDLINE, Embase and Cochrane CENTRAL were searched from inception to September 2025. Randomised controlled trials and observational studies reporting ADA measurement in adults with PsA receiving bDMARDs were included. The risk of bias was assessed using the Cochrane Risk of Bias Tool 2 and the Risk of Bias in Non-randomised Studies of Interventions. RESULTS: 28 studies (19 randomised controlled trials and 9 observational studies) were included. ADA prevalence varied widely between bDMARDs and across studies of the same drug and was not directly comparable due to immunoassay heterogeneity. The highest ADA prevalence was observed with adalimumab, infliximab and golimumab followed by ustekinumab, ixekizumab, certolizumab pegol and guselkumab, while secukinumab and etanercept demonstrated very low or absent immunogenicity. Across tumour necrosis factor (TNF) inhibitor studies, ADAs were consistently associated with lower serum drug levels and reduced clinical response, while concomitant methotrexate was associated with lower ADA prevalence. In contrast, serum drug level and clinical outcome data for interleukin (IL)-17, IL-12/23 and IL-23 inhibitors were limited or lacking. Immunogenicity-related adverse events were uncommon, and evidence was insufficient to establish an association with ADAs across bDMARDs. CONCLUSION: ADA prevalence in PsA varies widely between bDMARDs and across studies of the same bDMARD. ADAs appear most clinically relevant for TNF inhibitors, whereas evidence for other biological classes remains limited. Immunoassay heterogeneity limits comparability, highlighting the need for standardised prospective studies. PROSPERO REGISTRATION NUMBER: CRD420251121662.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kimpton J, Akpabio A, Watts A, et al. Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review. RMD Open. 2026. PMID: 42618212. doi:10.1136/rmdopen-2026-007140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。